Abstracts tagged "proteomics"

Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Samir Rachid Zaim¹, Adam Savage¹, Mark Gillespie¹, Christy Bennett¹, lynne Becker¹, LauraKay Moss², Marie Feser², Jess Edison³, Ted R Mikuls⁴, Michael Holer², kevin Deane² and Xiao-Jun Li¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³Walter Reed Military Medical Center, Bethesda, MD, ⁴Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
Abstract Number: 0962 • ACR Convergence 2023
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Irene Choi¹, Courtney Yu², Francesco Boin¹, Elizabeth Volkmann³, Stephanie Stanford² and Nunzio Bottini⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of California, San Francisco, CA
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass¹, Mehdi Nouraie¹, Yingze Zhang¹, Bryant England², Ted Mikuls³, Gail Kerr⁴, Andreas Reimold⁵, Kevin Gibson¹, Marilyn Glassberg⁶, Paul Dellaripa⁷, Tracy Doyle⁷, Chester Oddis⁸ and Dana Ascherman⁸, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵North Texas Veterans Administration Health Care System, Dallas, TX, ⁶Loyola University Chicago Stritch School of Medicine, Chicago, IL, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
Abstract Number: 0611 • ACR Convergence 2022
Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis
Jennifer Amsler¹, Constance Beaudouin², Morgane LeGall³, Géraldine Falgarone⁴, François Rannou⁵, Léa Tourneur³ and Véronique Witko-Sarsat³, ¹Institute Cochin, Schoenenwerd, Switzerland, ²Hôpital Privé de Provence, Aix-en-Provence, France, ³Institute Cochin, Paris, France, ⁴Hôpital Avicenne, Paris, France, ⁵Hôpital Cochin, Paris, France
Background/Purpose: Favoring apoptosis of neutrophils infiltrating the joints of patients suffering from rheumatoid arthritis (RA) and perpetuating inflammation has recently been discussed as an alternative…
Abstract Number: 2135 • ACR Convergence 2022
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
James C Waddington¹, Ruoyi Zhou¹, Orla Coleman¹, Bruna Wundervald², Andrew Parnell³, Vinod Chandran⁴, Lara Fallon⁵, Douglass Chapman⁶, Remy Pollock⁷, Shibing Deng⁸, Oliver FitzGerald⁹, Stephen R Pennington¹⁰ and Philip J Mease¹¹, ¹Atturos, Dublin, Ireland, ²Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, ³Hamilton Institute, Maynooth University, Kildare, Ireland, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Canada ULC, Kirkland QC, Canada, ⁸Pfizer Inc, Waterford, MI, ⁹Conway Institute, University College Dublin, Dublin, Ireland, ¹⁰Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
Abstract Number: 0616 • ACR Convergence 2022
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Liam O'Neil¹, XIAOBO MENG¹, Caitin McFadyen¹, Marvin Fritzler² and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
Abstract Number: 0650 • ACR Convergence 2022
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
Shudan Wang¹, Masako Suzuki², Daming Shao³, Muhammad Hamza Bukhari⁴, Brianna Lally⁵, Michael Belmont⁶, Jennifer Aguilan², Simone Sidoli², Anna Broder⁷ and J. Michelle Kahlenberg⁸, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Norwalk Hospital/Yale University, Norkwalk, VA, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Audrey Hagiwara¹, Moumita Bose¹, Aleksandr Stotland¹, Aleksandra Binek¹, Koen Raedschelders¹, Janet Wei¹, C. Noel Bairey Merz¹, Sarah Parker¹, Jennifer Van Eyk¹, Daniel Wallace¹, Mariko Ishimori² and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Health System, Los Angeles, CA
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Maria Luque-Tevar³, Pilar Font¹, Montserrat Romero-Gomez², Desiree Ruiz-Vilchez⁴, Sara Remuzgo-Martinez⁵, Raquel Lopez Mejias⁶, María Carmen Ábalos-Aguilera⁷, Rafaela Ortega-Castro¹, José Perez-Venegas⁸, Mª Dolores Ruiz-Montesinos⁸, Carmen Dominguez⁸, Carlos Rodriguez-Escalera⁹, Carmen Romero-Barco⁹, Antonio Fernandez-Nebro¹⁰, Natalia Mena Vazquez¹⁰, Jose Luis Marenco¹¹, Julia Uceda Montañez¹¹, Charo Santos¹², Nuria Barbarroja¹, Mª Angeles Aguirre¹³, Alejandro Escudero-Contreras², Eduardo Collantes¹, Miguel Ángel González-Gay¹⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Reina Sofia University Hospital, Cordoba, Cordoba, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶IDIVAL, Santander, Spain, ⁷Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁸Virgen Macarena University Hospital, Sevilla, Spain, ⁹Virgen de la Victoria Hospital, Málaga, Spain, ¹⁰Regional University Hospital of Málaga, Málaga, Spain, ¹¹Virgen de Valme University Hospital, Sevilla, Spain, ¹²Virgen de Valme University Hospital, Málaga, Spain, ¹³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Paul Newcombe¹, Richard A. Furie², Yoshiya Tanaka³, Wendy White⁴, Dominic Sinibaldi⁴, Philip Brohawn⁴, Mark Lazarus¹, Nicola Ferrari¹, Raj Tummala⁴, Hussein Al-Mossawi¹, Andre Nogueria da Costa⁵, Daniel Muthas⁵ and Madhu Ramaswamy⁴, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].